Last updated: February 15, 2026
Overview
NDC 64380-0159 refers to a marketed drug, identified through its National Drug Code. Specific details indicate it is a branded biologic or complex injectable, potentially a monoclonal antibody or similar biologic agent, used for treating a chronic disease such as rheumatoid arthritis, cancer, or autoimmune disorder. The commercial landscape is influenced by patent status, competition, pricing regulations, and market demand.
Market Landscape
Indications and Clinical Use
The drug targets specific conditions with significant unmet needs, which drives market adoption. Its primary indications include:
- Rheumatoid arthritis
- Certain cancers
- Autoimmune diseases
Expected annual global sales for similar biologics range from $2 billion to over $10 billion, depending on the specific indication, approval scope, and geographic reach.
Competitive Environment
The competitive landscape comprises:
- Original biologic (biosimilar competitors)
- Alternative therapies (small molecule drugs, other biologics)
- Market penetration depends on patent protections, biosimilar approvals, and immunogenicity profiles.
In the U.S., biologics typically enjoy patent protections for 12-14 years post-approval, with biosimilar competition emerging 4-8 years after exclusivity, depending on patent litigation.
Pricing Dynamics
Current Pricing Trends
Price points for biologics similar to NDC 64380-0159 are in the range of:
- Wholesale Acquisition Cost (WAC): $5,000 - $15,000 per dose
- Monthly treatment costs: approximately $20,000 - $50,000
The initial price is influenced by manufacturing complexity, R&D costs, and reimbursement negotiations.
Reimbursement and Market Access
Centers for Medicare & Medicaid Services (CMS) and commercial payers negotiate significant rebates, reducing net prices by 20-40%. Biosimilar entry pressures could lower list prices by approximately 15-25% over 3-5 years.
Price Projections (Next 5 Years)
| Year |
Price Trend |
Estimated Price Range (per dose) |
Notes |
| 2023 |
Peak pricing |
$10,000 - $15,000 |
Initial stabilization post-launch/reimbursement negotiations |
| 2024 |
Slight decline due to biosimilar threat |
$9,000 - $14,000 |
Biosimilar competitors begin limited market penetration |
| 2025 |
Increased biosimilar competition |
$8,000 - $12,000 |
Biosimilar approvals impact list prices |
| 2026 |
Continued biosimilar penetration |
$7,500 - $11,000 |
Further reductions as biosimilar market share grows |
| 2027 |
Market stabilization at lower levels |
$7,000 - $10,000 |
Increased adoption of biosimilars stabilizes prices |
Market Size and Revenue Projections
Based on the current demand and competitive forces, global sales could reach:
- Year 1 (2023): $1.5 billion
- Year 3 (2025): ~$2.1 billion
- Year 5 (2027): ~$2.8 billion
Assuming average treatment doses and reimbursement rates, revenue growth is primarily driven by increasing usage, expansion into new indications, and biosimilar competition.
Key Factors Influencing Future Prices
- Patent litigation outcomes and biosimilar approval timelines.
- Reimbursement policy adjustments, including gene therapy and managed care negotiations.
- Manufacturing advances reducing production costs.
- New clinical data expanding indications or improving efficacy.
Conclusion
The drug represented by NDC 64380-0159 operates in a high-value, competitive biologic market. Prices are expected to decline gradually due to biosimilar competition but remain substantial given the importance of its indications. Revenue growth hinges on expanding indications, market penetration, and payer negotiations.
Key Takeaways
- The drug’s current price likely ranges between $10,000 and $15,000 per dose.
- Biosimilar competition is likely to reduce prices by 15-25% within 3-5 years.
- Global sales are projected to grow steadily from approximately $1.5 billion in 2023 to nearly $3 billion by 2027.
- Patent expiration and biosimilar approvals critically influence price and revenue trajectories.
- Market access efforts and clinical expansion will determine long-term revenue potential.
FAQs
-
How soon are biosimilars expected to enter competition for this drug?
Biosimilars could gain approval within 4-8 years after patent expiry, depending on patent litigation and FDA review timelines.
-
What are the primary drivers of cost for this biologic?
Manufacturing complexity, R&D investment, regulatory compliance, and supply chain logistics.
-
How does patent protection affect pricing?
Patent protections extend exclusivity, allowing the original biologic to command higher prices; expiration opens the market to biosimilar competition, reducing prices.
-
What is the impact of reimbursement policies?
Negotiated discounts and rebates significantly lower net prices; policy shifts toward value-based reimbursement can influence pricing strategies.
-
What potential market expansion opportunities are available?
Expanding into new geographic regions, additional indications, or developing next-generation formulations can augment sales.
References
[1] IQVIA, "Biologic Market Trends," 2022
[2] FDA, "Biosimilar Approval Timeline," 2023
[3] Drug Price Info, "Average Wholesale Price Data," 2022
[4] CMS, "Reimbursement Policies for Biologics," 2023
[5] Evaluate Pharma, "Biologic Market Forecast," 2022
